相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
Tingting Jiang et al.
ACTA PHARMACEUTICA SINICA B (2021)
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Moshe Talpaz et al.
LEUKEMIA (2021)
Mitogen-activated protein kinases are involved in cucurbitacin D-induced antitumor effects on adult T-cell leukemia cells
Duo Wang et al.
INVESTIGATIONAL NEW DRUGS (2021)
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
V Subbiah et al.
ANNALS OF ONCOLOGY (2021)
Molecular Modelling Studies on Pyrazole Derivatives for the Design of Potent Rearranged during Transfection Kinase Inhibitors
Swapnil P. Bhujbal et al.
MOLECULES (2021)
Structure-activity relationship analysis of 3-phenylpyrazole derivatives as androgen receptor antagonists
Wenya Han et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2020)
Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma
Tim J. Peterson et al.
ANNALS OF PHARMACOTHERAPY (2020)
MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo
Xianli Tong et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance
Ning Sun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Anaplastic lymphoma kinase inhibitors: an updated patent review (2014-2018)
Yi-Min Liu et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2020)
Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib
John Nemunaitis et al.
FUTURE ONCOLOGY (2020)
Recent advances in targeted small-molecule inhibitor therapy for non-small-cell lung cancer-An update
Shubham Atal et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2020)
A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib
Qing-Yun Chong et al.
PHARMACOLOGICAL RESEARCH (2020)
Advances in Targeting RET-Dependent Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2020)
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naive and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer
Mi Ran Yun et al.
CLINICAL CANCER RESEARCH (2020)
Advances in the computational development of androgen receptor antagonists
Xueping Hu et al.
DRUG DISCOVERY TODAY (2020)
The discovery and development of binimetinib for the treatment of melanoma
Brian Tran et al.
EXPERT OPINION ON DRUG DISCOVERY (2020)
Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer
Joan Rou-En Choo et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy
Andrea Sartore-Bianchi et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
Erdafitinib for the treatment of metastatic bladder cancer
Kamaneh Montazeri et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2020)
Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development
Brooke Benner et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
Jose Trigo et al.
LANCET ONCOLOGY (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
Koichi Ando et al.
CANCERS (2020)
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein
Holger Fischer et al.
NEURO-ONCOLOGY (2020)
The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with anFLT3Mutation
Kyriaki Tzogani et al.
ONCOLOGIST (2020)
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
Constantine S. Tam et al.
BLOOD (2020)
Pharmacological and clinical properties of lorlatinib in the treatment ofALK-rearranged advanced non-small cell lung cancer
Haidar Eldarsa et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenstrom's macroglobulinemia
Naohiro Sekiguchi et al.
CANCER SCIENCE (2020)
Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
Andrew J. Piper-Vallillo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia
Yue Zhong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Jean-Yves Blay et al.
LANCET ONCOLOGY (2020)
ALK-Rearranged Non-SmallCell Lung Cancer in 2020:Real-WorldTriumphs in an Era of MultigenerationALK-InhibitorSequencing Informed by Drug Resistance Profiling
Malinda Itchins et al.
ONCOLOGIST (2020)
Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation
Evgeny N. Imyanitov et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015-2019)
Peng-Fei Wang et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2020)
Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor
Shanada Monestime et al.
DRUGS IN R&D (2020)
Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: A retrospective analysis in neuroendocrine tumor patients
Aman Chauhan et al.
Oncotarget (2020)
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Mrinal Gounder et al.
LANCET ONCOLOGY (2020)
Poly(ADP-ribose) polymerase inhibition: past, present and future
Nicola J. Curtin et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report
Zi-yan Yang et al.
FRONTIERS IN ONCOLOGY (2020)
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)
Liling Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
[Ga-68]Ga-DOTA-TOC: The First FDA-Approved Ga-68-Radiopharmaceutical for PET Imaging
Ute Hennrich et al.
PHARMACEUTICALS (2020)
Neratinib augments the lethality of [regorafenib plus sildenafil]
Laurence Booth et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib
Tanja K. Eggersmann et al.
BIODRUGS (2019)
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Shuang Qin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Bryan D. Smith et al.
CANCER CELL (2019)
Lenvatinib: A Review in Hepatocellular Carcinoma
Zaina T. Al-Salama et al.
DRUGS (2019)
Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.
Junning Cao et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pyrotinib combined with capecitabine in women with HER2+metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study.
Zefei Jiang et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Quizartinib (AC220): a promising option for acute myeloid leukemia
Fang Zhou et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
Danielle Golub et al.
FRONTIERS IN ONCOLOGY (2019)
Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry
Alejandra Martinez-Chavez et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2019)
Design, synthesis of orally bioavailable novel anaplastic lymphoma kinase (ALK) inhibitor diphenylaminopyrimidine analogs and efficacy study on NCI-H2228 xenografts mice model
Debasis Das et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S. Tam et al.
BLOOD (2019)
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial
Sarah R. Brown et al.
BMC CANCER (2019)
Entrectinib: First Global Approval
Zaina T. Al-Salama et al.
DRUGS (2019)
ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Y. Song et al.
HEMATOLOGICAL ONCOLOGY (2019)
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
William D. Tap et al.
LANCET (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells
Paul Dent et al.
ONCOGENE (2019)
Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
Niki Karachaliou et al.
ONCOTARGETS AND THERAPY (2019)
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Shuyan Dai et al.
CELLS (2019)
Fibroblast Growth Factor Receptor Functions in Glioblastoma
Ana Jimenez-Pascual et al.
CELLS (2019)
Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Zaina T. Al-Salama
DRUGS (2019)
Mitogen-Activated Protein Kinases: Functions in Signal Transduction and Human Diseases
Ritva Tikkanen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)
Xiaotian Kong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
LBA40FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
A Vogel et al.
ANNALS OF ONCOLOGY (2019)
Role of Androgen Receptor in Prostate Cancer: A Review
Kazutoshi Fujita et al.
WORLD JOURNAL OF MENS HEALTH (2019)
Neratinib protects pancreatic beta cells in diabetes
Amin Ardestani et al.
NATURE COMMUNICATIONS (2019)
Brigatinib: Novel ALK Inhibitor for Non-Small-Cell Lung Cancer
Sara A. Spencer et al.
ANNALS OF PHARMACOTHERAPY (2019)
Ribociclib in HR+/HER2-Advanced or Metastatic Breast Cancer Patients
Kaitlin Rascon et al.
ANNALS OF PHARMACOTHERAPY (2019)
Design, synthesis, and biological evaluation of thieno[3,2-d]pyrimidine derivatives as potential simplified phosphatidylinositol 3-kinase alpha inhibitors
Xiuyan Yang et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2019)
Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials
Zhihang Tao et al.
CLINICAL DRUG INVESTIGATION (2019)
Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update
Priyancy G. Jain et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects
Xiaoyun Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations
Claudia Trojaniello et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies
Liwei Lang et al.
CELLS (2019)
Erdafitinib to treat urothelial carcinoma
K. S. Hanna
DRUGS OF TODAY (2019)
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
Baohui Han et al.
BRITISH JOURNAL OF CANCER (2018)
Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer
Angela Musella et al.
CANCER TREATMENT REVIEWS (2018)
US Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer
Harpreet Singh et al.
CLINICAL CANCER RESEARCH (2018)
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma
Yihebali Chi et al.
CLINICAL CANCER RESEARCH (2018)
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Anand Shah et al.
CLINICAL CANCER RESEARCH (2018)
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
Chengyuan Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays
Wenfeng Lu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Tivozanib for the treatment of renal cell carcinoma
Matteo Santoni et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities
Kathleen N. Moore et al.
GYNECOLOGIC ONCOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Michael Wang et al.
LANCET (2018)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Enhancer of zeste homolog 2 (EZH2) inhibitors
Nitya Gulati et al.
LEUKEMIA & LYMPHOMA (2018)
Role of Bruton's tyrosine kinase in B cells and malignancies
Simar Pal Singh et al.
MOLECULAR CANCER (2018)
Insights into the biogenesis, function, and regulation of ADP-ribosylation
Michael S. Cohen et al.
NATURE CHEMICAL BIOLOGY (2018)
Targeting oncogenic transcription factors by polyphenols: A novel approach for cancer therapy
Chitra Rajagopal et al.
PHARMACOLOGICAL RESEARCH (2018)
A comprehensive review on Brigatinib - A wonder drug for targeted cancer therapy in non-small cell lung cancer
Silky Bedi et al.
SAUDI PHARMACEUTICAL JOURNAL (2018)
Enasidenib for the treatment of acute myeloid leukemia
James Dugan et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
Dazhi Liu et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
Olmutinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATP-binding cassette subfamily G member 2 in vitro and in vivo
Zhiqiang Zhang et al.
ACTA PHARMACEUTICA SINICA B (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
The role of tivozanib in advanced renal cell carcinoma therapy
Bernard Escudier et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Guoshuang Shen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
Yvette L. Kasamon et al.
ONCOLOGIST (2018)
Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer
Yongkun Sun et al.
THYROID (2018)
Emerging EZH2 Inhibitors and Their Application in Lymphoma
Jennifer K. Lue et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2018)
59PDFinal analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]
R S Finn et al.
ANNALS OF ONCOLOGY (2018)
PARPs in genome stability and signal transduction: implications for cancer therapy
Luca Palazzo et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2018)
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn et al.
BLOOD (2018)
Ixazomib for the treatment of multiple myeloma
Paul G. Richardson et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma
Balbina Garcia-Reyes et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors
Darren S. Sigal et al.
Oncotarget (2018)
Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
Wei Zhang et al.
FRONTIERS IN PHARMACOLOGY (2018)
Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy
Tiziana Vavala et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis
Richard M. Stone et al.
BLOOD ADVANCES (2018)
ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation.
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Acalabrutinib: First Global Approval
Anthony Markham et al.
DRUGS (2018)
Cobimetinib: A Novel MEK Inhibitor for Metastatic Melanoma
Jessie Signorelli et al.
ANNALS OF PHARMACOTHERAPY (2017)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
Ying Chen et al.
CLINICAL CANCER RESEARCH (2017)
Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs)
Laura Cosmai et al.
JOURNAL OF NEPHROLOGY (2017)
Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents
Yu Liu et al.
ONCOTARGET (2017)
Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors
Sourav Kalra et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib
Sulman Basit et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors
Sandra N. Milik et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Midostaurin for the treatment of acute myeloid leukemia
Mrinal M. Patnaik
FUTURE ONCOLOGY (2017)
SAFETY RUN-IN OF COPANLISIB IN COMBINATION WITH RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN'S LYMPHOMA
J. Gerecitano et al.
HEMATOLOGICAL ONCOLOGY (2017)
Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond
Daniela Di Lisi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
Toshimitsu Yamaoka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
Rui-Hua Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
Tjeerd Barf et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2017)
PARPing for balance in the homeostasis of poly(ADP-ribosyl)ation
Harald Schuhwerk et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2017)
CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib
Bahar Laderian et al.
SEMINARS IN ONCOLOGY (2017)
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
Esther S. Kim et al.
TARGETED ONCOLOGY (2017)
Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer
Yvette N. Lamb et al.
TARGETED ONCOLOGY (2017)
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia
Marlise R. Luskin et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib
Thomas Lee Collier et al.
NATURE COMMUNICATIONS (2017)
Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment
David Gyori et al.
CANCERS (2017)
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
Cynthia X. Ma et al.
CLINICAL CANCER RESEARCH (2017)
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments
Geraldine O'Sullivan Coyne et al.
DRUGS (2017)
Cell cycle proteins as promising targets in cancer therapy
Tobias Otto et al.
NATURE REVIEWS CANCER (2017)
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma
Nicole R. Infarinato et al.
CANCER DISCOVERY (2016)
Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression
Sarah E. Woodfield et al.
BMC CANCER (2016)
Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation
Yasushi Yoshimura et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor
Shruti Rakesh Tiwari et al.
CLINICAL BREAST CANCER (2016)
Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor
Ferdinandos Skoulidis et al.
CLINICAL CANCER RESEARCH (2016)
FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
Erin Larkins et al.
CLINICAL CANCER RESEARCH (2016)
Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors
Dima A. Sabbah et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2016)
Evaluation of rucaparib and companionydiagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy
Zachary B. Jenner et al.
FUTURE ONCOLOGY (2016)
Novel agents in the treatment of multiple myeloma: a review about the future
Leonard Naymagon et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
Maria Menichincheri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase
Wei-Sheng Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
Elena Ardini et al.
MOLECULAR CANCER THERAPEUTICS (2016)
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
M. Pavel et al.
NEUROENDOCRINOLOGY (2016)
Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma
Sarah L. Greig
TARGETED ONCOLOGY (2016)
Lenvatinib: A Review in Refractory Thyroid Cancer
James E. Frampton
TARGETED ONCOLOGY (2016)
Cyclin-Dependent Kinases as Coregulators of Inflammatory Gene Expression
M. Lienhard Schmitz et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers
Kwaku Appiah-Kubi et al.
TUMOR BIOLOGY (2016)
Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor A Review of Pharmacodynamics and Clinical Development
Amy S. Clark et al.
JAMA ONCOLOGY (2016)
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
Alessio Amatu et al.
BRITISH JOURNAL OF CANCER (2015)
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
Helen Y. Zou et al.
CANCER CELL (2015)
Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma
Scott X. Atwood et al.
CANCER CELL (2015)
Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic
Elizabeth R. Tucker et al.
CANCER RESEARCH (2015)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
Panobinostat: First Global Approval
Karly P. Garnock-Jones
DRUGS (2015)
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor
Christian Rolfo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination
Philip Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
Catriona Jamieson et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
Michael R. Migden et al.
LANCET ONCOLOGY (2015)
PARPs and ADP-Ribosylation: 50 Years ... and Counting
W. Lee Kraus
MOLECULAR CELL (2015)
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
Helen Y. Zou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Tivozanib: Status of Development
Muhammad Omer Jamil et al.
CURRENT ONCOLOGY REPORTS (2015)
Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer
Mariacarmela Santarpia et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2015)
Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy
Qiaoling Sun et al.
CANCER BIOLOGY & THERAPY (2014)
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia
Naveen Pemmaraju et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review
Eugen F. Mesaros et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2014)
Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia
Mark Levis
FUTURE ONCOLOGY (2014)
New and emerging HDAC inhibitors for cancer treatment
Alison C. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Nucleo-cytoplasmic transport as a therapeutic target of cancer
Giovanni Luca Gravina et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
M. Raymond V. Finlay et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
Ted W. Johnson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer
Justin M. Drake et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
Pasi A. Jaenne et al.
LANCET ONCOLOGY (2014)
Evolution of androgen receptor targeted therapy for advanced prostate cancer
Yien Ning Sophia Wong et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
BRAF inhibitors in cancer therapy
Carolina Hertzman Johansson et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Targeting of Smoothened for therapeutic gain
Martial Ruat et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
Hedgehog signalling pathway inhibitors as cancer suppressing agents
Trieu N. Trinh et al.
MEDCHEMCOMM (2014)
Bruton's Tyrosine Kinase (BTK) Inhibitors in Clinical Trials
Jan A. Burger
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2014)
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Seth A. Wander et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
Epidermal growth factor receptor targeting in cancer: A review of trends and strategies
Chetan Yewale et al.
BIOMATERIALS (2013)
Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF
Simon Giroux
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Cancer heterogeneity: implications for targeted therapeutics
R. Fisher et al.
BRITISH JOURNAL OF CANCER (2013)
Cell survival and metastasis regulation by Akt signaling in colorectal cancer
Ekta Agarwal et al.
CELLULAR SIGNALLING (2013)
Targeting transcription factors: promising new strategies for cancer therapy
Jennifer E. Yeh et al.
CURRENT OPINION IN ONCOLOGY (2013)
Fibroblast Growth Factor Receptor Inhibitors
Suneel B. V. S. Kumar et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors
Carlo G. Tocchetti et al.
EUROPEAN JOURNAL OF HEART FAILURE (2013)
Panobinostat in lymphoid and myeloid malignancies
Amit Khot et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
Kerstin Maria Kampa-Schittenhelm et al.
MOLECULAR CANCER (2013)
Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling while Specifically Inducing Apoptosis in FLT3-Activated Leukemia Cells
Ruwanthi N. Gunawardane et al.
MOLECULAR CANCER THERAPEUTICS (2013)
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
Ningshu Liu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis
Zhaohua Zheng et al.
BIOCHEMICAL JOURNAL (2012)
SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors
Timothy Forsyth et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Proteasome inhibitors in multiple myeloma: 10 years later
Philippe Moreau et al.
BLOOD (2012)
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Nicola J. Clegg et al.
CANCER RESEARCH (2012)
Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence
Sai-Hong Ignatius Ou
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Targeting the Hedgehog signaling pathway for cancer therapy
Yiwei Li et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia
R. Swords et al.
LEUKEMIA (2012)
Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance
Gerrit J. P. Dijkgraaf et al.
CANCER RESEARCH (2011)
FMS-like tyrosine kinase 3 inhibitors: a patent review
Jongkook Lee et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2011)
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment
Enrique Grande et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools
Olaf Merkel et al.
MOLECULAR CANCER THERAPEUTICS (2011)
The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients
Evangelos Terpos
LEUKEMIA RESEARCH (2011)
Somatostatin Receptor-Targeted Anti-Cancer Therapy
Li-Chun Sun et al.
CURRENT DRUG DELIVERY (2011)
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Kristy J. Gotink et al.
ANGIOGENESIS (2010)
PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity
J. F. M. Leal et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature
Yujia Dai
EXPERT OPINION ON THERAPEUTIC PATENTS (2010)
Inhibitors of anaplastic lymphoma kinase: a patent review
Karen L. Milkiewicz et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2010)
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
S. Whittaker et al.
ONCOGENE (2010)
Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and-2 Mutant Tumors
Philip Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Hedgehog-Gli Signaling Pathway Inhibitors as Anticancer Agents
Neeraj Mahindroo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor
Qi Chao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma
Robert L. Yauch et al.
SCIENCE (2009)
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases
Florence I. Raynaud et al.
CANCER RESEARCH (2007)
The role of histone deacetylases (HDACs) in human cancer
Santiago Ropero et al.
MOLECULAR ONCOLOGY (2007)
Neurotrophin signaling:: many exciting surprises!
J. C. Arevalo et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity
HR Tsou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Trk receptor tyrosine kinases: A bridge between cancer and neural development
A Nakagawara
CANCER LETTERS (2001)
Preparation and evaluation of tumor-targeting peptide-oligonucleotide conjugates
W Mier et al.
BIOCONJUGATE CHEMISTRY (2000)
分享论文
